Home / Treatments / Ozempic
Ozempic denials: what the review data shows
Independent reviewers have decided 139 published cases where an insurer denied Ozempic — and they overturned the insurer 65.5% of the time. A denial for Ozempic is a starting position, not a final answer.
Published decisions
139
2001–2026
Overturned
65.5%
91 denials reversed
By condition
Published outcomes when Ozempic was denied for these conditions.
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 45 | 73.3% |
| Type 2 Diabetes | 22 | 68.2% |
| Type 1 Diabetes | 15 | 80% |
| Diabetes | 13 | 61.5% |
| Type 2 Diabetes Mellitus | 12 | 83.3% |
| Prediabetes | 12 | 25% |
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Ozempicwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.